SCOPUS 정보 검색 플랫폼

The Lancet Oncology

Volumn 12, Issue 3, 2011, Pages 217-

10-year analysis of the ATAC trial: Wrong conclusion? - Authors' reply

(7) Cuzick, Jack a Sestak, Ivana a Baum, Michael b Buzdar, Aman c Howell, Anthony d Dowsett, Mitch e Forbes, John F f

a IMPERIAL CANCER RESEARCH FUND (United Kingdom)

b UNIVERSITY COLLEGE LONDON (United Kingdom)

c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER (United States)

d UNIVERSITY OF MANCHESTER (United Kingdom)

e ROYAL MARSDEN HOSPITAL (United Kingdom)

f UNIVERSITY OF NEWCASTLE (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; PLACEBO; TAMOXIFEN;

ANGINA PECTORIS; BREAST CANCER; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG MONITORING; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOMETRIUM CANCER; FOLLOW UP; GYNECOLOGIC DISEASE; HUMAN; HYPERTENSION; LETTER; MUSCULOSKELETAL DISEASE; OSTEOLYSIS; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; STROKE; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

EID: 79952013513 PISSN: 14702045 EISSN: None Source Type: Journal
DOI: 10.1016/S1470-2045(11)70050-X Document Type: Letter

Times cited : (3)

References (5)

1
- 78649603622
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
- for the ATAC/LATTE investigators
- Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11:1135-1141. for the ATAC/LATTE investigators.
- (2010) Lancet Oncol , vol.11 , pp. 1135-1141
- Cuzick, J.¹ Sestak, I.² Baum, M.³

2
- 33746408229
- Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial
- The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group
- Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006, 7:633-643. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group.
- (2006) Lancet Oncol , vol.7 , pp. 633-643

3
- 0344233260
- Meta-analysis of vascular and neoplastic events associated with tamoxifen
- Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003, 18:937-947.
- (2003) J Gen Intern Med , vol.18 , pp. 937-947
- Braithwaite, R.S.¹ Chlebowski, R.T.² Lau, J.³ George, S.⁴ Hess, R.⁵ Col, N.F.⁶

4
- 79960720836
- US Food and Drug Administration, (accessed Dec 21, 2010).
- Highlights of prescribing information US Food and Drug Administration, (accessed Dec 21, 2010). http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020541s024s025lbl.pdf.
- Highlights of prescribing information

5
- 45849143717
- Primary endpoints for randomised trials of cancer therapy
- Cuzick J Primary endpoints for randomised trials of cancer therapy. Lancet 2008, 371:2156-2158.
- (2008) Lancet , vol.371 , pp. 2156-2158
- Cuzick, J.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.